

Myrbetriq (mirabegron) compared to sugar pill to reduce current symptoms for overactive bladder

What is this drug used for?	To treat and reduce symptoms of overactive bladder
Who might consider taking it?	Adults age 18 and older with overactive bladder
Who should not take it?	No contraindications
Recommend monitoring	Baseline blood pressure then periodically during treatment

Myrbetriq Study Findings

1,328 adults with overactive bladder symptoms for 3 or more months were give Myrbetriq or a sugar pill daily for 12 weeks. Here’s what happened:

What difference did Myrbetriq make?	People given sugar pill	People given Myrbetriq (50 mg a day)	People given Myrbetriq (100 mg a day)
Did Myrbetriq help?			
Myrbetriq users had fewer incontinence episodes per 24 hours	-1.13 episodes	-1.47 episodes	-1.63 episodes
Myrbetriq users had fewer micturitions per 24 hours	-1.05	-1.66	-1.75
Myrbetriq users voided more volume per micturition	7 ml	18.2 ml	18 ml
Myrbetriq users had a lower level of urgency	-0.08	-0.19	-0.21
Myrbetriq users had fewer urgency incontinence episodes per 24 hours	-0.89	-1.32	-1.45
Myrbetriq users had fewer nocturia episodes per 24 hours	-0.38	-0.57	-0.57
Did Myrbetriq have side effects?			
<i>Life threatening side effects</i>		None observed	
No difference between Myrbetriq and sugar pill			
<i>Symptom side effects</i>			
Fewer had hypertension	6.6% (30 in 453)	6.1% (27 in 442)	4.9% (21 in 433)
More had a urinary tract infection	1.8% (8 in 453)	2.7% (12 in 442)	3.7% (16 in 433)
More had a headache	2% (9 in 453)	3.2% (14 in 442)	3% (13 in 433)
Similar in dry mouth	1.5% (7 in 453)	0.5% (2 in 442)	2.1% (9 in 433)

How long has Myrbetriq been available?
 Myrbetriq was approved by the FDA June 28, 2012.

Sources:

1. Nitti V, Auerbach S, Martin N, et al. Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder. *J Urol*. 2013; 189(4):1388-95.
2. Mirabegron. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Hudson, OH. Available at: <http://online.lexi.com>. Accessed October 31, 2014.
3. U.S Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=202611&TABLE1=OB_Rx. Accessed October 31, 2014.
4. Myrbetriq (R) [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; 2012.